Prognostic value of normal stress myocardial perfusion imaging and ventricular function in Japanese patients with chronic kidney disease: a study based on the J-ACCESS-3 database
- 210 Downloads
The purpose of this study is to test the hypothesis that a normal myocardial perfusion imaging (MPI) study in chronic kidney disease (CKD) can provide benign prognostic information for the prediction of major cardiovascular events.
The study group consisted of 431 CKD patients (males, 64%; mean age, 72 ± 11 years) with normal SPECT imaging. Based on SPECT image and QGS data, 331 had a summed stress score of 3 or less, a summed difference score of 1 or less and normal cardiac function (males; end-systolic volume (ESV) ≤ 60 ml, females; ESV ≤ 40 ml, males, ejection fraction (EF) ≥ 49%; females, EF ≥ 50%).
During a 3-year follow-up period, there were a total of 27 major cardiovascular events, including cardiac death (n = 3), sudden death (n = 3), and acute coronary syndrome (n = 3), and 19 were hospitalized because of congestive heart failure. Kaplan–Meier analysis showed that the number of major cardiovascular events in patients with higher eGFR of ≥ 15 ml/min) were very few, and regarded as low risk. According to the eGFR status, namely < 15 (n = 58), 15 to < 30 (n = 97), 30 to < 45 (n = 131), ≥ 45 (n = 45), the higher cardiac event rate was observed in patients with eGFR of < 15 ml/min among the four groups. The major cardiovascular event rate in patients with the lowest eGFR (< 15) was twice as much than that in patients with eGFR of ≥ 30 ml/min. Lower hemoglobin (males, < 12 g/dl; females, < 11 g/dl) and higher CRP (CPR ≥ 0.3 mg/dl) were also the predictors of increased risk.
Normal stress SPECT images confer a benign prognosis in patients with CKD, but care must be taken for severely reduced renal function, which was associated with higher cardiac event.
KeywordsPrognosis SPECT Radionuclide imaging Chronic kidney disease eGFR
The J-ACCESS-3 study was supported by a grant from the Japan Cardiovascular Research Foundation. We thank the many physicians and technologists in the 62 hospitals who participated in the J-ACCESS-3 study for their cooperation.
Compliance with ethical standards
Conflict of interest
All authors have no COI.
This article does not contain any studies with human participants performed by any of the authors.
- 4.Nakamura S, Kawano Y, Nakajima K, Hase H, Joki N, Hatta T, et al. Prognostic study of cardiac events in Japanese patients with chronic kidney disease using ECG-gated myocardial perfusion imaging: final 3-year report of the J-ACCESS 3 study. J Nucl Cardiol. 2017; https://doi.org/10.1007/s12350-017-0880-5.
- 5.Joki N, Hase H, Kawano Y, Nakamura S, Nakajima K, Hatta T, et al. Myocardial perfusion imaging for predicting cardiac events in Japanese patients with advanced chronic kidney disease: 1-year interim report of the J-ACCESS 3 investigation. Eur J Nucl Med Mol Imaging. 2014;41:1701–9.CrossRefPubMedGoogle Scholar
- 10.Berman DS, Hachamovitch R, Kiat H, Cohen I, Cabico JA, Wang FP, et al. Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol. 1995;26:639–47.CrossRefPubMedGoogle Scholar
- 11.Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.CrossRefPubMedGoogle Scholar
- 12.Hachamovitch R, Berman DS, Shaw LJ, Kiat H, Cohen I, Cabico JA, et al. Incremental prognostic value of myocardial perfusion single-photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. Circulation. 1998;97:535–43.CrossRefPubMedGoogle Scholar
- 14.Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117:1283–91.CrossRefPubMedGoogle Scholar
- 28.Soneson H, Hedeer F, Arévalo C, Carlsson M, Engblom H, Ubachs JF, et al. Development and validation of a new automatic algorithm for quantification of left ventricular volumes and function in gated myocardial perfusion SPECT using cardiac magnetic resonance as reference standard. J Nucl Cardiol. 2011;18:874–85.CrossRefPubMedGoogle Scholar
- 29.Gimelli A, Liga R, Magro S, Novo S, Pedrinelli R, Petronio AS, et al. Evaluation of left ventricular mass on cadmium-zinc-telluride imaging: validation against cardiac magnetic resonance. J Nucl Cardiol 2017.Google Scholar